CD79A and respiratory tract infectious disorder: Accomplishing this goal will require an improved understanding of the complex immunobiology of upper respiratory infection with Bp, and the development of vaccines that prime IgG, IgA, and Th1/Th-17 responses in the respiratory mucosa.